文献速递呼吸道感染

氟喹诺酮类药物与自发性气胸风险的病例-时间-对照研究

Association of fluoroquinolones with the risk of spontaneous pneumothorax: nationwide case-time-control study.
PubMed 文献 · Thorax · 2025-02-17

基于法国全国医保数据库的病例-时间-对照研究,纳入2017至2022年因自发性气胸住院的成人。氟喹诺酮暴露与气胸风险升高相关(校正OR 1.59,95%CI 1.14–2.22),但阿莫西林关联更强(OR 2.25,95%CI 2.07–2.45),提示基础感染而非抗生素本身导致气胸。

要点

  • 氟喹诺酮使用与自发性气胸风险升高相关,校正OR为1.59。
  • 阿莫西林与气胸的关联更强(OR 2.25),提示感染是主要混杂因素。
  • 结果不支持氟喹诺酮对肺结缔组织的因果性毒性作用。

核心结论

  • 氟喹诺酮和阿莫西林使用均与自发性气胸风险升高相关,阿莫西林关联更强,提示基础感染而非抗生素个体因果效应。

研究设计与样本

  • 法国全国医保数据库(SNDS)的病例-时间-对照研究,纳入2017至2022年因自发性气胸住院的成人≥18岁。
  • 氟喹诺酮暴露比较入院前30天风险期与三个更早的参考期,并校正时间变化混杂因素。
  • 使用无事件参照组校正暴露趋势偏倚,并以阿莫西林对照控制适应证偏倚。

主要发现

  • 246例氟喹诺酮暴露的气胸病例中,63例在30天风险期暴露,128例在参考期暴露。
  • 3316例阿莫西林暴露病例中,1210例在30天风险期暴露,1603例在参考期暴露。
  • 校正暴露趋势和协变量后,氟喹诺酮的OR为1.59(95%CI 1.14–2.22),阿莫西林为2.25(95%CI 2.07–2.45)。

临床怎么用

  • 临床遇到自发性气胸患者时,应评估近期抗生素使用及基础感染情况。
  • 不应因潜在气胸风险而回避有指征的氟喹诺酮使用,需权衡感染本身风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Fluoroquinolones can cause severe collagen-associated adverse effects, potentially impacting the pulmonary connective tissue. We investigated the association between fluoroquinolones and spontaneous pneumothorax. METHODS: A case-time-control study was performed using the nationwide French reimbursement healthcare system database (SNDS). Cases were adults ≥18 years admitted for spontaneous pneumothorax between 2017 and 2022. For each case, fluoroquinolone use was compared between the risk period immediately preceding the admission date (days -30 to -1), and three earlier reference periods (days -180 to -151, -150 to -121, -120 to -91), adjusting for time-varying confounders. OR estimates were corrected for potential exposure-trend bias using a reference group without the event (matched on age, sex, chronic obstructive pulmonary disease history, calendar time). Amoxicillin use was studied similarly to control for indication bias. RESULTS: Of the 246 pneumothorax cases exposed to fluoroquinolones (63.8% men; mean age, 43.0±18.4 years), 63 were exposed in the 30-day risk period preceding pneumothorax and 128 in the reference periods. Of the 3316 amoxicillin cases (72.9% men; mean age, 39.4±17.6 years), 1210 were exposed in the 30-day risk period and 1603 in the reference ones. OR adjusted for exposure-trend and covariates was 1.59 (95% CI 1.14 to 2.22) for fluoroquinolones and 2.25 (2.07 to 2.45) for amoxicillin. CONCLUSION: An increased risk of spontaneous pneumothorax was associated with both fluoroquinolone and amoxicillin use, with an even higher association for amoxicillin. This strongly suggests the role of the underlying infections rather than a causal effect of the individual antibiotics and can be considered reassuring regarding a potential lung connective toxicity of fluoroquinolones.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Bénard-Laribière A, Pambrun E, Kouzan S, et al. Association of fluoroquinolones with the risk of spontaneous pneumothorax: nationwide case-time-control study. Thorax. 2025. PMID: 39393909. doi:10.1136/thorax-2024-221779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。